middle.news
Nexalis Completes IRX-616a Phase 1 Trial with No Serious Adverse Events
1:06pm on Friday 31st of July, 2026 AEST
•
Healthcare
Read Story
Nexalis Completes IRX-616a Phase 1 Trial with No Serious Adverse Events
1:06pm on Friday 31st of July, 2026 AEST
Key Points
IRX-616a Phase 1 dosing completed without serious adverse events
Linlithgow Family Office cancels remaining funding commitment
Clinical trials for IRX-211 and IRX-616a temporarily suspended
SRX-25 Phase 1 planning advances with intellectual property focus
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexalis Therapeutics (ASX:NX1)
OPEN ARTICLE